Free Submission Public Relations &
Deutsch English

Global Parkinson's Disease Market 2012-2016

Global Parkinson's disease market: 1.7% CAGR growth expected between 2012-2016

Print article Print article
2014-01-28 10:34:01 - Global Parkinson's Disease Market 2012-2016 - a new market research report on

The Global Parkinson´s Disease market is to grow at a CAGR of 1.67 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rise in the aging population. The Global Parkinson´s Disease market has also been witnessing the transition toward using drugs that have new mechanisms of action. However, weak pipeline landscape could pose a challenge to the growth of this market.

Vaccine development is undergoing significant advancements in the market; special focus is given to neurodegenerative diseases such as Parkinson´s disease. As the drugs used to treat patients with Parkinson´s have only been able to address the symptoms, a huge unmet need lies in this region. There isn´t a single drug available that



can modify the course of the disease. AFFiRiS AG, an Australian pharmaceutical company, is involved in the first-ever Phase I clinical development trial for Parkinson´s disease (PD01A). The vaccine targets the protein alpha-Synuclein, which is responsible for the onset of the disease. PD01A is expected to encourage disease modifying effects and not symptomatic relief.

One of the main drivers propelling the growth of the market is the steadily growing aging population worldwide. The increasing aging population is contributing to the growth of the market. The number of patients suffering from Parkinson´s disease is increasing owing to the increasing aging population both in the developing and developed nations.

One of the major challenges faced by the market is the weak pipeline landscape. Most products in the pipeline lack molecules which can potentially achieve blockbuster status in the near future.

The key vendors dominating this space include GlaxoSmithKline plc, Novartis AG, Orion Corp., and Teva Pharmaceuticals Industries Ltd. The other vendors mentioned AbbVie Inc., Acadia Pharmaceuticals Inc., Avicena Group Inc., BoehringerIngelheim GmbH, Impax Laboratories Inc., Lundbeck A/S, Newron Pharmaceuticals SpA, Solvay Pharmaceuticals Inc., and Valeant International SRL.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact